Clinical Trial Update: ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures [Phase 3]

View source ↗

Summary

Phase III study of ZD6474 (ZACTIMA) in patients with non-small cell lung cancer who failed prior EGFR therapy completed. Results were posted on 2012-03-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ZACTIMA (ZD6474) (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2012-03-26